Loading
Life sciences · Journal article
Journal of Modern Medicine · October 10, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently considered one of the most common chronic liver diseases and is closely associated with the increasing prevalence of obesity, insulin resistance, type 2 diabetes mellitus, and other cardiometabolic disorders. Unlike the previously used term “non-alcoholic fatty liver disease”, the modern concept of MASLD primarily focuses on the presence of hepatic steatosis in combination with metabolic risk factors. This approach reflects the evolving understanding of the pathogenesis of the disease and emphasizes the central role of metabolic dysfunction in the development of liver injury